Company overview

MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA, offers one of the industry’s most innovative portfolios, not only of products, but also of services and technologies, to prevent, treat and control diseases across all major farm and companion animal species. We maintain commercial offices in more than 50 countries and business operations in more than 150 markets, and run a global network of manufacturing and R&D facilities.

Our mission – The Science of Healthier Animals – guides all of our work. Healthier animals mean a sustainable food supply, protection for humans against diseases passed from animals, and longer, healthier lives for pets. We understand that veterinary surgeons, farmers and pet owners face challenges that are wider, more complex and evolving faster than ever, not least being how animal health connects with our own. We are committed to providing the products, technologies, services and insights to help meet their needs.

Global trade, migration and climate change can increase the spread of highly infectious diseases that devastate animal populations, threaten human health, and disrupt the food supply. We know that only a fast and flexible approach will control the spread of disease and protect our communities and food supplies. Our global reach allows us to react quickly to changing disease landscapes around the world and to provide local solutions for diseases such as foot-and-mouth disease, peste des petits ruminants, bluetongue virus, and porcine reproductive and respiratory syndrome.

We understand that global food production must double by 2050 to meet the demands of a growing world population, placing even greater importance on platforms that improve productivity. Rising incomes in many countries translate into more people with the desire, time and money to keep pets in the home. As pet ownership increases, so does the need for state-of-the-art products and services to help pets live longer and healthier lives. To help pet owners control parasites, for example, we introduced the first chewable tablet for dogs that is effective against fleas and certain tick species for up to 12 weeks, nearly three times longer than monthly products.  

Our robust R&D pipeline spans key therapeutic areas, providing a solid platform for further pharmaceutical and vaccine advances in veterinary medicine. Still, our customers expect more from us than just medicines. As a multi-species global company, we respond readily to the demands of our dynamic industry, working in close collaboration with our customers to deliver the information, technologies and veterinary services to meet their needs around the world. We further drive the pace of scientific innovation by combining our in-house expertise with an active business development and in-licensing program.